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Abstract: Background: Zinc is an essential micronutrient that impacts host–pathogen interplay at
infection. Zinc balances immune responses, and also has a proven direct antiviral action against
some viruses. Importantly, zinc deficiency (ZD) is a common condition in elderly and individuals
with chronic diseases, two groups with an increased risk for severe severe coronavirus disease
2019 (COVID-19) outcomes. We hypothesize that serum zinc content (SZC) influences COVID-19
disease progression, and thus might represent a useful biomarker. Methods: We ran an observational
cohort study with 249 COVID-19 patients admitted in Hospital del Mar. We have studied COVID-19
severity and progression attending to SZC at admission. In parallel, we have studied severe acute
respiratory syndrome coronavirus 2 (SARS-CoV2) replication in the Vero E6 cell line modifying
zinc concentrations. Findings: Our study demonstrates a correlation between serum zinc levels and
COVID-19 outcome. Serum zinc levels lower than 50 µg/dL at admission correlated with worse
clinical presentation, longer time to reach stability, and higher mortality. Our in vitro results indicate
that low zinc levels favor viral expansion in SARS-CoV-2 infected cells. Interpretation: Low SZC is
a risk factor that determines COVID-19 outcome. We encourage performing randomized clinical
trials to study zinc supplementation as potential prophylaxis and treatment with people at risk of
zinc deficiency.
Keywords: SARS-CoV-2; zinc; clinical outcomes
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1. Introduction
Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) result
in a systemic disease with a variety of outcomes, from no symptoms to severe and diverse
pathologies, with pneumonia and acute respiratory distress symptom being the most
common. Therefore, a better knowledge of risk factors determining severity is essential for
treating patients in the early stages of COVID-19.
Zinc (Zn2+) is an essential trace element required for maintaining a variety of fun-
damental biological processes, due to its functions as a cofactor, signaling molecule, and
structural element. One of the most significant roles of zinc in our body is its broad effect
on the immune system [? ? ], as both the adaptive and the innate immunity, are affected by
zinc levels. Consequently, zinc deficiency (ZD), due to low zinc intake or malabsorption,
results in an immune imbalance that ultimately causes a major public health problem
with high prevalence in elderly and individuals with chronic diseases [? ]. In adaptive
immunity, zinc affects T lymphocyte maturation, differentiation, and cytokine production.
B cell activation and plasma cell differentiation depend on zinc signaling as well [? ? ].
In innate immunity, zinc has an anti-inflammatory role [? ]. Concretely, ZD is associated
with higher levels of interleukin (IL)-1beta and tumor necrosis factor (TNF)-alfa [? ], as
well as with altered activities of monocytes, neutrophils, and natural killer (NK) cells [? ? ?
]. Correspondingly, ZD results in increased susceptibility to inflammatory and infectious
diseases, including acquired immune deficiency syndrome, measles, malaria, tuberculosis,
and pneumonia [? ].
In this context, zinc supplementation trials have been carried out to reduce morbidity
and mortality in developing countries with high ZD incidence. Importantly, zinc sup-
plementation significantly reduced the duration of respiratory tract infections caused by
rhinoviruses and coronaviruses [? ]. Moreover, zinc has been shown to have a direct an-
tiviral action [? ]. Remarkably, in vitro zinc inhibited the binding of the SARS coronavirus
RNA-dependent RNA polymerase to its template and the subsequent elongation, as well
as viral replication in a cell culture [? ]. Altogether, zinc status might condition COVID-19
severity, and zinc supplementation could be a useful tool to impact COVID-19 outcome.
In this work, we focus our observational study on the putative association between
the zinc status of hospitalized COVID-19 patients with disease progression and clinical
outcomes. Moreover, we address in cell culture the potential of zinc supplementation to
directly block SARS-CoV-2 multiplication in Vero E6 infected cells.
2. Materials and Methods
2.1. Study Design and Participants
An observational cohort study was performed at Hospital del Mar in Barcelona (Spain).
This is a 400-bed, tertiary university hospital in Barcelona that provides healthcare to an
urban area of 500,000 people. All patients admitted with COVID-19 for ≥48 h between 9
March and 1 April 2020 were included. COVID-19 was defined as a SARS-CoV-2 infection,
confirmed by quantitative PCR (qPCR) performed in nasopharyngeal samples obtained by
trained personnel at hospital admission, and by fulfilling clinical diagnostic criteria. These
include any of the following: respiratory symptoms (dyspnea, cough, sore throat, changes
in taste/smell) and chest X-ray findings (uni-or bilateral interstitial infiltrates) that made
the diagnosis probable in the current epidemiological situation. The Institutional Ethics
Committee of Hospital del Mar of Barcelona approved the study, and due to the nature
of the retrospective data review, waived the need for informed consent from individual
patients (CEIm-2020/9352).
2.2. Procedures
Demographic, clinical, epidemiological, and the whole-episode (laboratory workup,
vital signs, treatment) data were extracted from electronic medical records using a standard-
ized data collection method. Comorbidity was collected individually and as the Charlson
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Comorbidity Index, a clinical score that relates long term-mortality to patient comorbidity.
It is considered the absence of comorbidity to be 0–1 points and high at >3 points.
Laboratory workups were systematized with an at-admission protocol that included
a fasting blood draw, complete kidney and liver profile, electrolytes, blood count, coagu-
lation profile, inflammatory markers (interleukin-6 (IL-6), serum ferritin), D-dimer, and
myocardial enzymes. Zinc and selenium levels were detected by electrochemiluminescence.
Follow-up laboratory workups in the clinical setting included C-reactive protein and IL-6,
which made possible to determine the IL-6 peak.
2.3. Definitions
2.3.1. Time to Recovery (TR)
Time to recovery (TR) or time to clinical stability was defined as the time elapsed
since the patient’s admission to oxygen saturation >94% (FiO2 = 21%), normalized level
of consciousness (baseline), heart rate <100 rpm, systolic blood pressure >90 mm Hg, and
body temperature <37.2 ◦C.
2.3.2. Clinical Severity
Clinical severity was assessed at admission with a modified early warning score
(MEWS) [? ]. The same score was used for the follow-up during the admission.
2.3.3. Low Zinc Levels
Since levels of zinc have a diurnal variation, all samples were collected through
a fasting blood draw at 8 am (±2 h). In our cohort, the Q1 was 50 µg/dL (7.6 µM).
According to previous publications, 50 µg/dL is a proper threshold of abnormally lower
zinc concentration to predict clinical signs [? ]. We considered this as a predictive factor the
lower range (<50 µg/dL).
2.4. Cell Culture
Vero E6 cells were grown as described [? ? ]. When indicated, fetal bovine serum (FBS)
was incubated according to the manufacturer’s instructions with Chelex 100 resin (Bio-Rad
Laboratories, Hercules, CA, USA) to generate Zn2+-free growth medium. ZnSO4 was
added as needed to the final medium to generate specific Zn2+ concentration conditions.
Chloroquine (Supelco, Darmstadt, Germany) was prepared in water at 10 mM and used at
the desired concentration.
2.5. Zinc Measurements
Cells were seeded and grown in multi-well 24 plates until reaching 80% of confluence.
Cells were incubated with 1 µM of FluoZin-3AM (Invitrogen, Darmstadt, Germany) or
25 µM of Zinquin (Sigma-Aldrich, Darmstadt, Germany) for 30 min at 37 ◦C (5% CO2) in
isotonic solution containing (in mM) 140 NaCl, 5 KCl, 1.2 CaCl2, 0.5 MgCl2, 5 glucose, and
10 Hepes (300 milliosmoles/liter, pH 7.4), plus different concentrations of Zn2+ and/or
chloroquine (CQ).Cells were then dissociated with Trypsin 0.05% in 0.53 mM EDTA, and
were washed with PBS 1x. Fluorescence was quantified using an LSRII flow cytometer.
Further analysis was performed using Flowing software (Perttu Terho, Turun yliopisto,
Turku, Finland).
For in vivo confocal imaging, cells grown on 22 mm coverslips were incubated with
Lysotracker, together with FluoZin-3AM or Zinquin, in a solution with 50 µM Zn2+ for
30 min; they were then washed twice with PBS and placed under the microscope in isotonic
solution for imaging with an SP8 Leica microscope (Wetzlar, Germany).
2.6. Viability Assays
Cells were exposed to different Zn2+ and CQ concentrations for 48 h. Then, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent was added to obtain
a final concentration of 0.5 mg/mL. Cells were incubated 2–3 h at 37 ◦C. After that, the
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supernatant was removed, and cells were resuspended in 100 µL of DMSO. The absorbance
was read at 570 nm.
2.7. Virus Infection and Quantification
Vero E6 cells were infected with SARS-CoV-2 strain hCoV-19/Spain/VH000001133/2020
(EPI_ISL_418860), and 48 h later viral RNA from the supernatant was extracted using the
Quick-RNA Viral Kit (Zymo Research, Irvine, CA, USA). SARS-CoV-2 production was
quantified by qPCR with the qScript XLT One-Step RT-qPCR ToughMix, ROX (Quanta Bio-
sciences, Berverly, USA), using the specific probe 2019-nCoV_N1-P, 5′-FAM-ACCCCGCATT
ACGTTTGGTGGACC-BHQ1-3′; as well as primers 2019-nCoV_N1-F, 5′-GACCCCAAAATC
AGCGAAAT-3′; and 2019-nCoV_N1-R, 5′-TCTGGTTACTGCCAGTTGAATCTG-3′ (Biomers,
Ulm, Germany).
2.8. Western Blot
Cells were treated with 0, 10, or 50 µM of Zn2+ and 10 µM of CQ for 24 h. Then, cells
were washed twice with cold PBS and lysed with 35 µL of lysis buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM DTT, 10 mM 13-GP, 0.1 mM Na3VO4,
and protease inhibitors). Lysates were vortexed for 30 min at 4 ◦C and centrifuged at
10,000× g to remove aggregates. Lysates were boiled at 95 ◦C and placed in ice for 1 min.
20 µL of each sample were loaded onto a 12% or 14% polyacrylamide gel. After transfer,
membranes were blocked with 5% milk in TBS-Tween 0.1% for 1 h at room temperature.
Primary antibodies were diluted in blocking solution—microtubule-associated proteins
1A/1B light chain 3B (LC3) (L8918, Sigma-Aldrich, Darmstadt, Germany) at 1:500, p62
(ab155686, Abcam, Cambridge, UK) at 1:1000, and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (ab8245, Abcam, Cambridge, UK) at 1:1000—and incubated overnight
at 4 ◦C. Anti-rabbit or anti-mouse horseradish peroxidase (HRP) secondary antibodies
(1:1000; GE Healthcare, Chicago, IL, USA) were used.
2.9. Statistical Analysis
A descriptive analysis of the main demographic characteristics of the cohort and
the main clinical (laboratory, treatment and outcome) characteristics of the episode was
done. Continuous and categorical variables were presented as median (interquartile range
(IQR)) and absolute number (percentage), respectively. A Mann–Whitney U-test, χ2 test,
and Fisher’s exact test were used to compare differences between individuals with serum
zinc levels above and below 50 µg/mL. Bi-variate comparisons and a multiple logistic
regression model studying the impact of at-admission serum zinc in in-hospital mortality
were fitted adjusting by age, sex, Charslon comorbidity index, and severity of the episode.
Taking into consideration the number of deaths observed, and to avoid overfitting the
model, we selected the most significant variables and those that provided a more general
characterization of the individuals. We excluded variables if they had collinearity with
MEWS or age. We created exploratory alternative models, including previously well-
known individual mortality risk factors, such as chronic kidney disease, lung disease,
or diabetes. We selected the final model adjusted by age, sex, severity, and Charslon
comorbidity index. Significance was a p-value <0.05. Stata 14 software was used.
In the in vitro assays, we applied either an unpaired Student’s t-test (when comparing
two conditions), or one-way analysis of variance (ANOVA) followed by a Bonferroni
post-hoc test (when comparing control with any other condition) was applied. All plots
comparisons and p values are described in figure legends. Analysis was performed using
GraphPad software (San Diego, CA, USA).
3. Results
3.1. Influence of SZC in COVID-19 Outcome
We included 249 consecutive adults admitted to the COVID-19 unit between 9 March
and 1 April 2020. The median age of participants was 65 (54–75) years, and 49% were
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female. Table ?? shows the baseline characteristics of the cohort and the differences between
individuals with SZC <50 µg/dL and ≥50 µg/dL at onset. Hypertension was the most
prevalent comorbidity. At admission, the overall severity according to MEWS score was
2 (1–3). Fever, cough, and dyspnea were the most common symptoms, with frequencies
of 203 (81%), 198 (79%), and 151 (60%), respectively. Inflammation was a hallmark of
the episode, with 224 (87.5%) individuals having abnormal IL-6 at admission and with a
median IL-6 of 42 pg/mL (15–89), a median C-reactive protein of 7.5 mg/dL (3.5–15.2), and
a median D-Dimer of 800 UI/l (470–1450). Almost all the individuals admitted during this
period received hydroxychloroquine. Other treatments were tocilizumab, dexamethasone,
and methylprednisolone, each of which were prescribed in a quarter of individuals. Seventy
patients (28%) were admitted to the intensive care unit (ICU), and 21 (9%) patients died
during hospitalization in this period.
Table 1. Main clinical characteristics of the cohort. Differences between individuals with plasma zinc at admission at
<50 mcg/dL and ≥50 mcg/dL.
Overall <50 µg/dL ≥50 µg/dL p-Value
Cohort Characteristics n = 249 n = 58 n = 191
Median age, years (IQR) 65 (54–75) 65 (59–75) 64 (53–74) 0.363
Male sex (%) 127 −51% 30 −51% 97 −51% 0.929
Comorbidities
Current smoker (%) 23 −9.30% 4 −7% 19 −10% 0.482
Hypertension (%) 141 −56% 33 −57% 108 −57% 0.962
Diabetes mellitus (%) 53 −21% 17 −29% 36 −19% 0.088
Chronic lung disease (%) 22 −9% 9 −16% 13 −7% 0.041
Chronic heart disease (%) 37 −14% 11 −19% 26 −14% 0.315
Chronic renal disease (%) 70 −12% 22 −38% 48 −25% 0.058
Chronic liver disease (%) 18 −7% 1 −2% 17 −9% 0.065
Dementia (%) 8 −3% 2 −3% 6 −3% 0.908
HIV infection (%) 5 −2% 1 −2% 4 −2% 0.865
Active cancer (%) 7 −3% 3 −5% 4 −2% 0.214
ACE inhibitors (%) 61 −24% 12 −21% 49 −26% 0.441
Charlson Comorbidy Index,
median (IQR) 1 (0–3) 1 (0–3) 1 (0–2) 0.247
Symptoms at onset
Median days since syntoms
onset (IQR) 7 (4–9) 6 (3–7) 7 (5–10) 0.005
Dyspnoea (%) 151 −60% 42 −72% 109 −57% 0.036
Fever (%) 203 −81% 45 −77% 158 −82% 0.377
Cough (%) 198 −79% 43 −74% 155 −81% 0.246
Diarrhea (%) 68 −27% 12 −21% 56 −29% 0.196
Clinical markers at onset
Median C-reactive protein
mg/dL (IQR) 7.5 (3.5–15.2) 14.6 (5–24) 7 (3–13) 0.037
Median lymphocyte
count/mL (IQR) 1.02 (0.71–1.4) 0.82
(0.57–
1.18) 1.1 (0.78–1.48) 0.598
Median interleukin (IL)-6
pg/mL (IQR) 42 (15–89) 77 (39–145) 32 (11–71) <0.001
Median lactate dehydrogenase
UI/l (IQR) 288 (241–345) 356 (275–483) 274 (231–362) 0.001
Median D-dimer UI/l (IQR) 800 (470–1450) 935 (540–1700) 800 (460–1215) 0.048
Median PaO2FiO2 ratio (IQR) 177 (100–299) 124 (91–181) 219 (106–314) <0.001
Median modified early warning
score (MEWS) (IQR) 2 (1–3) 2 (2–3) 2 (1–3) 0.005
Median serum zinc,
mcg/mL (IQR) 61 (50–71) 43 (39–48) 66 (58–74) <0.001
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Table 1. Cont.
Overall <50 µg/dL ≥50 µg/dL p-Value
Treatment
Hydroxycholoroquine (%) 248 −99.50% 58 −100% 190 −99% 0.372
Azythromicin (%) 231 −95% 57 −95% 174 −95% 0.766
Tocilizumab (%) 55 −23% 23 −40% 32 −17% <0.001
Dexamethasone (%) 64 −26% 24 −41% 40 −21% <0.001
Methylprednisolone (%) 59 −24% 26 −45% 33 −17% <0.001
Clinical Outcomes
Median Time to clinical
recovery days (IQR) 10 (6–18) 25 (14–36) 8 (5–14) <0.001
Intensive care unit (ICU)
admission (%) 70 −28% 36 −62% 34 −18% <0.001
Death (%) 21 −9% 12 −21% 9 −5% <0.001
IQR (Interquartile Range).
SZC median at admission was 61 µg/dL (9.3 µM), with 58 (23%) of the individuals
presenting SZC < 50 µg/dL. Individuals with serum zinc levels <50 µg/dL had higher
prevalence of chronic kidney disease and chronic respiratory disease (9% vs. 2%, p = 0.024,
and 16% vs. 7%, p = 0.041, respectively). Moreover, this group had a more severe clinical
presentation MEWS score (2 (2–3) vs. 2 (1–3); p = 0.005) and significantly greater inflamma-
tion, measured by the nonspecific marker C-reactive protein (14.6 mg/dL vs. 7 mg/dL;
p = 0.03) and the more specific IL-6 (77 pg/mL vs. 32 pg/mL; p < 0.001). At admission, SZC
correlated negatively with inflammation measured by IL-6 (Pearson’s r = −0.307; p < 0.001)
(Figure ??A), and interestingly, also correlated negatively with the highest value of IL-6
during the episode (Pearson’s r = −0.317; p < 0.001) (Figure ??B). This negative correlation
was also observed with the nonspecific inflammatory markers, such as ferritin (Pearson’s
r = −0.227; p = 0.001) and C-reactive protein (Pearson’s r = −0.315; p < 0.001) (Figure ??C).
We also found a correlation between SZC at admission and procoagulation factors, such as
D-dimer (Pearson’s r = −0.317; p = 0.048).
The median time to clinical recovery in our cohort was 9.5 days (6–18). However,
subjects with SZC at admission <50 µg/dL needed longer TR compared with those with
zinc ≥ 50 µg/dL: 25 days (14–36) vs. 8 (5–14) days, respectively; p < 0.001. Moreover, SZC
at admission was correlated negatively with the TR of the episode (Pearson’s r = −0.441;
p < 0.001) (Figure ??D). Two alternative multivariable regression models were created, one
using zinc as a quantitative continuous variable, and by adjusting for age, sex, severity,
and Charlson comorbidity index, the TR was associated with low SZC at admission (beta-
coefficient = −0.21 (95% CI= 0.316 to −0.097; p < 0.001)) (Table S2A). In an alternative
model, adjusting serum zinc as a dichotomous variable (SZC < 50 µg/dL or ≥50 µg//dL)
and adjusting by age, sex severity, and Charslon comorbidity index, serum zinc lev-
els <50 µg/dL negatively impacted the TR (beta-coefficient = 14.1 (95% CI = 4.29–23.94;
p = 0.004) (Table S2B).
Twenty-one individuals (9%) died during this period. SZC at admission was signif-
icantly higher among individuals who survived (62 µg/dL (52–72)) compared to those
who died (49 µg/dL (42–53); p < 0.001). Individuals with SZC at admission <50 µg/dL
had a mortality of 21%, which was significantly higher compared to the 5% mortality in
individuals with zinc at admission≥50 µg/dL (p < 0.001). We fitted a multivariable logistic
regression model, including 249 patients with data for all variables (228 survivors and 21
non-survivors). When adjusting by age, sex, Charlson comorbidity index, and severity, the
model showed an odds ratio (OR) for in-hospital death of 0.94 (95% CI = 0.899 to 0.982;
p = 0.006) per unit increase of serum zinc at admission. In an alternative age-, sex-, severity-
, and Charslon comorbidity index-adjusted model with the predictive variable SZC at
admission <50 µg/dL, the adjusted OR for in-hospital death was 3.2 (95% CI = 1.01 to 10.12;
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p = 0.047). Other models, adjusting by individual mortality risk factors, along with age,
sex, and severity, did not show differences with the final model for in-hospital mortality.
Figure 1. Correlation between serum zinc levels at admission, inflammatory markers, and clinical
outcome. (A) Zinc and IL-6 at admission. (B) Zinc at admission and highest value of IL-6 during the
episode. (C) Zinc and C-reactive protein at admission. (D) Serum zinc content at admission and time
to clinical stability.
3.2. Impact of Cellular Zinc Content on SARS-CoV2 Expansion
Besides its impact on immune response, SZC might influence viral expansion [? ].
Therefore, to obtain a wider picture of determinants involved in COVID-19 severity derived
from SZC, we carried out assays in a cell culture to study the direct impact of cellular
zinc content on SARS-CoV-2 multiplication. We used three different concentrations of
zinc in the extracellular medium—0, 10, and 50 µM ZnSO4—to reproduce zinc deficiency,
physiological zinc, and zinc supplementation, respectively. As expected, intracellular
Zn2+ content changed in Vero E6 cells incubated for 30 min in different extracellular
Zn2+ concentrations and monitored with Fluozin 3AM and Zinquin fluorescence probes.
Confocal images showed that the FluoZin 3AM signal was mainly localized in the lysosomal
compartment, while the Zinquin signal was intracellularly spread (Figure ??B). After 48 h
incubation, different Zn2+ content solutions did not impact cell viability (Figure ??C).
Importantly, extracellular zinc concentrations affected SARS-CoV-2 multiplication, as
measured by qPCR from the cell culture supernatant at 48 h post-infection. SARS-CoV-2
multiplication was increased at 0 µM Zn2+ when compared to those values at 10 and 50
µM Zn2+ concentrations (Figure ??D). This indicates that zinc levels affect the SARS-CoV-2
life cycle in infected cells.
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Figure 2. Evaluation of zinc homeostasis in SARS-CoV-2 infection. (A,B). Intracellular zinc content
measurement using FluoZin-3AM and Zinquin probes in Vero E6 cells. (A). Flow cytometry in cells
incubated for 30 min with 0, 10, and 50 µM extracellular Zn2+ content. Intensity expressed in arbitrary
units (AU) (n = 3; * p < 0.05, *** p < 0.001; Bonferroni-corrected one-way ANOVA compared to 0
Zn2+). (B). Confocal images of living cells incubated with FluoZin-3AM (up) or Zinquin (bottom)
and Lysotyracker in 50 µM Zn2+ extracellular medium. Scale bar = 10 µm. (C). Viability MTT
assay in cells incubated with 0, 10, and 50 µM extracellular Zn2+ content for 48 h. Data expressed
in percentage compared to control condition (10 µM Zn2+) (n = 12; Bonferroni-corrected one-way
ANOVA compared to 10 µM Zn2+). (D). Quantification in supernatant of viral RNA copies by qPCR
in cells infected with SARS-CoV-2 and collected at 48 h. Data expressed in percentage compared to
control condition (10 µM Zn2+) (n = 3; ** p < 0.01; Bonferroni ANOVA compared to 10 µM Zn2+).
3.3. Assessment of Zinc Properties as a Potentiator of Chloroquine’s Antiviral Action
It has been suggested that Zn2+ may potentiate CQ antiviral activity, because CQ
acts as a zinc ionophore [? ]. Zinc supplementation, in combination with CQ, has been
used to treat COVID-19 patients, showing benefits [? ? ]. To test the potentiation effect
against COVID-19, we carried out SARS-CoV-2 infections at different zinc concentrations
in the absence or presence of 10 µM CQ; the concentration was chosen based on previously
published effective concentrations [? ? ]. Neither the CQ toxicity nor its antiviral activity
were affected by zinc levels (Figure ??A,B). CQ caused a significant reduction in SARS-CoV-
2 RNA genome copies compared to control cells (59.68% ± 18.46%; p < 0.05) (Figure ??B).
Next, we addressed whether CQ increases the intracellular Zn2+ content by acting as a
zinc ionophore, as was previously proposed [? ]. For this, we evaluated the cytosolic Zn2+
levels in cells grown under different CQ concentrations, using flow cytometry analysis
and FluoZin-3AM and Zinquin labels (Figure ??C). Notably, an increased zinc signal was
observed in a CQ dose-dependent manner using FluoZin-3AM, but not with Zinquin
(Figure ??C). This indicates that CQ modifies lysosomal Zn2+ content, but is not a zinc
ionophore. As the described increase in lysosomal pH caused by CQ blocks autophagic
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flux [? ] and inhibition of autophagy impairs SARS-CoV-2 replication [? ], we studied the
impact on autophagy of different zinc concentrations in the presence and the absence of
CQ (Figure ??D–F). As expected, at 10 µM, CQ treatment autophagy blockade resulted
in an increased LC3II/I ratio and p62 expression (Figure ??E,F). However, no significant
effects on these values were observed at different Zn2+ levels in the absence or presence of
CQ. Altogether, our results indicate that CQ and zinc do not potentiate each other.
Figure 3. Evaluation of zinc potentiation of chloroquine antiviral action. (A) Viability MTT assay in cells incubated with
10 µM chloroquine (CQ) in 0, 10, and 50 µM Zn2+ content for 48 h (n = 15; Bonferroni-corrected one-way ANOVA compared
to 10 µM Zn2+). (B) Quantification in the supernatant of viral RNA copies by qPCR in cells infected with SARS-CoV-2
treated with 10 µM CQ in 0, 10, and 50 µM Zn2+, and collected at 48 h. Data expressed in percentage compared to control
condition (10 µM Zn2+ without CQ, Figure ??D) (n = 3; Bonferroni-corrected one-way ANOVA compared to 10 µM CQ
in 10 µM Zn2+). (C) Flow cytometry in cells incubated for 30 min with 0, 10, and 50 µM extracellular Zn2+ content using
FluoZin-3AM and Zinquin probes. Intensity expressed in arbitrary units (AU) (n ≥ 4; *** p < 0.001; Bonferroni-corrected
one-way ANOVA compared to 0 µM Zn2+ from each probe). (D–F) Western blot analysis from cells incubated for 24 h in 0,
10, and 50 µM Zn2+ with or without 10 µM CQ. Antibodies against microtubule-associated proteins 1A/1B light chain 3B
(LC3), p62, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (D) Representative blot. (E,F) Quantification of the
bands for LC3 ((E) n ≥ 10) and p62 ((F) n ≥ 7) (Bonferroni-corrected one-way ANOVA compared to 10 µM Zn2+ or 10 µM
CQ in 10 µM Zn2+; ** p < 0.01, *** p < 0.001 unpaired t-test comparing conditions with and without CQ).
4. Discussion
Our study demonstrates a correlation between serum zinc levels and COVID-19 out-
come. SZC lower than <50 µg/dL at admission correlated with worse clinical presentation,
longer time to recovery, and higher mortality. These results might suggest that SZC im-
pacts COVID-19 severity, and its adjustment might also constitute an early therapeutic
intervention point. These results are in accordance with the observational studies carried
out by other groups with smaller cohorts [? ? ]. Moreover, we show that SZC affects the
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SARS-CoV-2 life cycle in infected cells. This effect, contrary to what it has been previously
suggested, does not seem to potentiate CQ activity.
The association between zinc and human health has been known for decades [? ].
Due to poor nutrition and subsequent low zinc intake, ZD remains a major nutritional
problem in multiple countries. In addition, elderly individuals are prone to ZD even in
developed countries, where the incidence ranges from 15% to 31%, depending on the age
and the country of study [? ]. Older adults are the group at higher risk for severe symptoms
and mortality from COVID-19 [? ]. In our retrospective observational study, with 249
COVID-19 patients admitted to Hospital del Mar, at admission 23% of them had SZC lower
than 50µg/dL, the cutoff associated with severe ZD and development of clinical signs [? ].
At onset, higher levels of inflammatory markers, such as IL-6 and C-reactive pro-
tein, were present in low-SZC patients (Figure ??A,C). The prognostic value of IL-6 and
C-reactive protein for COVID-19 severity has already been described [? ]. In this work,
we add SCZ as a novel early predictor for COVID-19 outcome. In addition, we observed
a robust negative correlation between zinc levels and the highest peak of IL-6 highest
peak (Figure ??B). These results suggest that COVID-19 patients with low SZC have an
exacerbated immune response. ZD is known to be associated with proinflammatory re-
sponses at infection, showing higher reactive oxygen species production and inflammatory
markers [? ? ]. An imbalance in cytokine production by cells of both innate and adaptive
immunity has also been reported [? ? ]. Several clinical trials using zinc supplementation
have been carried out to prevent and treat infections and inflammatory conditions [? ? ].
Zinc supplementation decreases the incidence of infection in elderly and improves cytokine
imbalance and oxidative stress markers [? ? ]. Thus, the idea of supplementing low SZC
COVID-19 patients with zinc in order to balance what has been called the cytokine storm
caused by SARS-CoV-2 is attractive. Reassuringly, zinc supplementation for the common
cold caused by rhino- and coronaviruses has been proven to reduce its duration and symp-
toms [? ]. Serum zinc content is a common and recommended biomarker to assess zinc
status and the risk of zinc deficiency morbidity [? ]. Nevertheless, it is also known that
upon acute infection, IL-6 promotes zinc internalization in hepatocytes [? ]. Therefore, we
cannot discard that the hypozincemia observed in COVID-19 patients might be caused
and worsened by a negative IL-6 production loop. As a consequence, one limitation of our
retrospective study is that our SZC measurements might not indicate the zinc nutritional
status of COVID-19 patients before infection.
In addition to the impact of zinc in the modulation of the antiviral immune response,
zinc has also been shown to have direct antiviral action [? ]. We have analyzed in vitro
the impact of zinc homeostasis in SARS-CoV-2 infection. Our results indicate that hy-
pozincemia favors viral expansion in the infected cell (Figure ??C). These results would
support that the poor clinical outcome observed in low-SZC patients is caused by the effect
of low zinc availability on both, inducing immune imbalance and increasing viral load by
promoting viral expansion in the infected cell. However, it is noteworthy that our in vitro
studies did not show a replication blockade in zinc supplementation conditions (50 µM,
Figure ??C), suggesting the need of a zinc ionophore to further increase cytosolic zinc
levels in order to block viral replication, as previously shown in vitro for herpes simplex,
picornavirus, arterivirus, and SARS-CoV (9,10).
During the beginning of the pandemic CQ was prescribed as a first-line treatment
in the acute presentation. The rationale was that CQ has been claimed to be a novel zinc
ionophore [? ], and had shown antiviral effects against SARS-CoV-2 in vitro [? ? ]. However,
clinical trials failed to demonstrate its beneficial effects against COVID-19 [? ? ]. Therefore,
it was suggested that zinc supplementation could potentiate its antiviral activity [? ]. In fact,
there was an observational study treating COVID-19 patients with CQ supplemented with
zinc that showed a reduction in mortality [? ? ]. In our results in vitro, cellular zinc content
did not modify CQ cytotoxicity, the autophagic flux blockade, or its antiviral action against
SARS-CoV-2. Moreover, we monitored intracellular zinc content both with Fluozin-3AM, a
probe previously done by Xue and colleagues that is retained mainly in lysosomes [? ], and
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with Zinquin, which presents more general intracellular staining. We conclude that CQ
is not a zinc ionophore, as previously claimed, because its effect on cellular zinc content
is restricted to the lysosomal compartment, probably by altering zinc transport at this
specific organelle (Figure ??). Thus, our study does not support the mechanistic rationale
of supplementing CQ treatments with zinc. The positive results observed by Carlucci and
collaborators in COVID-19 patients treated with zinc sulfate should not be attributed to a
CQ potentiation effect [? ].
This study has some limitations, since we cannot prove causality. Thus, zinc levels at
admission could be impacted by other factors, such as acute phase reactants themselves [? ].
Moreover, this is a single center study with a limited sample size. However, the study also
has important strengths, since it has been conducted in a hospital with a large population
area that is a representative area of an European city affected by the COVID-19 pandemic.
All patients were attended in the COVID-19 unit under the same guidelines, with well-
protocolized clinical procedures and with a centralized database that made the management
of data uniform, reducing the weakness of the clinical data collection. This makes the
quality and quantity of data coming from the COVID-19 unit reliable and homogeneous.
5. Conclusions
This work aims to focus clinical attention on serum zinc content in COVID-19 patients.
Our analysis has shown a robust correlation between low SZC and COVID-19 severity and
mortality. The cause is likely to be a combination of immune system imbalance and a direct
benefit of viral replication. Thus, we propose SZC as a novel and additional parameter to
predict COVID-19 outcome. It is then urgent to start clinical trials supplementing patients
with low SZC at admission with zinc to reestablish zinc homeostasis. It should be also
recommended to promote zinc supplementation programs targeted to people at risk of
zinc deficiency, such as the elderly, in order to reduce COVID-19’s severity.
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